← Search & browse all drugs
RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS › Glucocorticoids
mometasone
R03BA07
Forms & Strengths
- Inhalation powder (Twisthaler): 110 mcg/inhalation, 220 mcg/inhalation
- Nasal spray: 50 mcg/actuation
- Topical cream: 0.1%
- Topical ointment: 0.1%
- Topical lotion: 0.1%
Adult Dosing
- Asthma (Twisthaler): 220 mcg twice daily; severe cases up to 440 mcg twice daily
- Allergic rhinitis: 2 sprays (100 mcg) in each nostril once daily
- Topical dermatoses: Apply thin film to affected areas once daily
Pediatric Dosing
- Asthma (Twisthaler, ages >=12 years): 110 to 220 mcg twice daily
- Allergic rhinitis (ages 2-11 years): 1 spray (50 mcg) in each nostril once daily
- Allergic rhinitis (ages >=12 years): 2 sprays (100 mcg) in each nostril once daily
Indications
- Maintenance treatment of asthma as prophylactic therapy
- Treatment of nasal symptoms of seasonal and perennial allergic rhinitis
- Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Mechanism of Action
- Synthetic 17-heterocyclic corticosteroid with high affinity for glucocorticoid receptors
- Exerts potent anti-inflammatory, antipruritic, and vasoconstrictive effects
- Involves inhibition of multiple cell types (mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures
- Known hypersensitivity to mometasone furoate or any ingredient in the formulation
- Untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex (for ophthalmic/systemic spread risks)
Adverse Reactions
- Oral candidiasis
- Pharyngitis, dysphonia, and cough (inhalation)
- Epistaxis, nasal burning, and irritation (nasal spray)
- Local skin atrophy, striae, telangiectasia, and secondary infection (topical)
- Hypothalamic-pituitary-adrenal (HPA) axis suppression with systemic absorption
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, cobicistat) may increase systemic exposure and risk of systemic corticosteroid effects
- Ritonavir may significantly increase plasma concentrations of inhaled mometasone
Curated Content: Needs Vetting Before Put to Clinical Use